Genmab earns millions on new Darzalex approval
Genmab’s core asset Darzalex has been approved in EU for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. It triggers a milestone payment of more than DKK 300 million (about USD 44 million) to the Danish company.
BY MARTIN HAVTORN PETERSEN
The EU Commission has approved Genmab’s lead asset, oncology drug Darzalex, for second line treatment of multiple myeloma. This is according to a press release from Genmab.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Genmab earns another USD 25 million from Darzalex sales
For abonnenter
Genmab’s Darzalex will not proceed to phase 2 in NHL
For abonnenter
